Generics North America (NAFTA) Industry Guide 2019-2028


Summary

The NAFTA Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.


Key Highlights

  • The North American Free Trade Agreement (NAFTA) is a trade agreement between the countries in North America: the US, Canada and Mexico. The generics industry within the NAFTA countries had a total market value of $88,125.3 million in 2023.The Canada was the fastest growing country, with a CAGR of 7% over the 2019-23 period.
  • Within the generics industry, the US is the leading country among the NAFTA bloc, with market revenues of $74,229.0 million in 2023. This was followed by Canada and Mexico, with a value of $7,717.8 and $6,178.6 million, respectively.
  • The US is expected to lead the generics industry in the NAFTA bloc, with a value of $98,531.3 million in 2028, followed by Canada and Mexico with expected values of $10,446.0 and $7,720.0 million, respectively.




Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the NAFTA generics market
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the NAFTA generics market
  • Leading company profiles reveal details of key generics market players’ NAFTA operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the NAFTA generics market with five year forecasts by both value and volume
  • Compares data from the US, Canada and Mexico, alongside individual chapters on each country




Reasons To Buy

  • What was the size of the NAFTA generics market by value in 2023?
  • What will be the size of the NAFTA generics market in 2028?
  • What factors are affecting the strength of competition in the NAFTA generics market?
  • How has the market performed over the last five years?
  • How large is the NAFTA generics market in relation to its regional counterparts?